Analyzing Emmaus Life Sciences (OTCMKTS:EMMA) and NeuroSense Therapeutics (NASDAQ:NRSN)

Valuation and Earnings

This table compares Emmaus Life Sciences and NeuroSense Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emmaus Life Sciences	$29.60 million	0.01	-$3.73 million	($0.09)	-0.07
NeuroSense Therapeutics	N/A	N/A	-$11.28 million	($0.85)	-1.01

Emmaus Life Sciences has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Emmaus Life Sciences and NeuroSense Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emmaus Life Sciences	-17.11%	N/A	-12.66%
NeuroSense Therapeutics	N/A	N/A	-286.31%

Institutional and Insider Ownership

7.4% of Emmaus Life Sciences shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 35.0% of Emmaus Life Sciences shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Emmaus Life Sciences has a beta of 6.2, suggesting that its stock price is 520% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Summary

Emmaus Life Sciences beats NeuroSense Therapeutics on 8 of the 9 factors compared between the two stocks.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.